As the diabetes epidemic continues to grow, practitioners are increasingly searching for medication solutions that can help patients to better manage their diabetes. This month, we have a recent slides series from the ADA showing the positive effects of adding-on SGLT-2 inhibitors to the medication regimen of patients on DPP-4’s …
Read More »Handbook of Diabetes, 4th Edition, Excerpt #10: Management of Type 2 Diabetes
Rudy Bilous, MD, FRCP Richard Donnelly, MD, PHD, FRCP, FRACP Lifestyle modification The starting points and mainstays of treatment for type 2 diabetes are diet and other modifications of lifestyle, such as increasing exercise and stopping smoking (Figure 11.1). The major aims are to reduce the weight of obese patients and …
Read More »Sitagliptin Use in Diabetic Patients with Heart Failure
There is some uncertainty in the literature about whether DPP-4 inhibitors are harmful to diabetic patients with heart failure….
Read More »ADA: Sulfonylureas Along with TZDs May Increase Risk for Fractures in Diabetes
A large database analysis has found that two oral diabetes drug classes, thiazolidinediones (TZDs) and sulfonylureas, both increase the risk for fractures when compared with metformin….
Read More »Diabetes Clinical Case Series, Excerpt #10, Endocrinology and Diabetes, The Basics, Part 2
Treatment of type 2 diabetes (T2DM) Education of patients is very important The importance of diet and exercise should be emphasized All patients should be reviewed by a dietitian for appropriate advice Measures to induce weight loss (most of these patients are overweight) should be encouraged/implemented In the initial phases …
Read More »Could Glucagon-like Peptide-1 (GLP-1) Agonists Be Delivered Intranasally?
Possibility of non-subcutaneous administration could increase patient compliance…. GLP-1 agonists are effective therapeutic options for treating diabetes. While their effectiveness has been established, compliance with these medications may be limited in some patients due to their subcutaneous route of administration and gastrointestinal adverse effects. In a recent prospective, double-blind, placebo-controlled …
Read More »Surprising Trends in the Use of Antidiabetic Drugs
Researchers track data on antidiabetic prescriptions dispensed from retail pharmacies in the US and note some interesting prescribing patterns. What is the most antidiabetic drug dispensed?… See more SGLT-2 Resources Despite the ability of nonpharmacological methods such as lifestyle interventions and bariatric surgery to improve type 2 diabetes outcomes, most …
Read More »Adding Vildagliptin to Metformin for Type 2’s
The results of adding vildagliptin to metformin….
Read More »Alternative GLP-1 Delivery Systems
Although glucagon-like peptide-1 (GLP-1) is highly biologically active following intravenous or subcutaneous injection, a non-injectable alternative for activating GLP-1 receptor signaling would clearly be desirable. Studies by Gutniak, Ahren and colleagues in Sweden have shown that GLP-1 formulated in buccal tablets is absorbed into the circulation and lowers blood glucose …
Read More »No Compelling Evidence Linking Incretin Therapies, Pancreatic Cancer
U.S. and European regulators have found no compelling evidence of a link between the drug class which includes GLP-1 analogs and DPP-4 inhibitors, and pancreas problems or pancreatic cancer….
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.